ALKERMES | ALKS - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 62.97B 12M 2025-09
Acadia Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 285.82M 639K 2024-09
Amgen USD 50B 2.43B 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Gilead Sciences USD 22.14B 5M 2025-09
Heron Therapeutics USD 140.64M 975K 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
J&J USD 39.44B 30M 2025-12
Malin Corporation EUR 0 0 2024-12
Merck USD 39.97B 6B 2025-09
Minerva Neurosciences USD 0 86.58M 2024-09
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Otsuka Holdings JPY 166.92B 6.35B 2025-12
Ovoca Bio EUR 0 0 2021-06
Pfizer USD 57.41B 93M 2025-09
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03